Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue: 2010-2018

Historic Non-Current Deffered Revenue for Neurocrine Biosciences (NBIX) over the last 8 years, with Dec 2018 value amounting to $18.1 million.

  • Neurocrine Biosciences' Non-Current Deffered Revenue rose 77.05% to $18.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $18.1 million, marking a year-over-year increase of 77.05%. This contributed to the annual value of $18.1 million for FY2018, which is 77.05% up from last year.
  • Neurocrine Biosciences' Non-Current Deffered Revenue amounted to $18.1 million in Q4 2018, which was up 49.62% from $12.1 million recorded in Q3 2018.
  • Over the past 5 years, Neurocrine Biosciences' Non-Current Deffered Revenue peaked at $18.1 million during Q4 2018, and registered a low of $1.9 million during Q4 2014.
  • For the 3-year period, Neurocrine Biosciences' Non-Current Deffered Revenue averaged around $11.0 million, with its median value being $10.2 million (2018).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first dropped by 5.30% in 2014, then soared by 445.07% in 2015.
  • Neurocrine Biosciences' Non-Current Deffered Revenue (Quarterly) stood at $1.9 million in 2014, then spiked by 445.07% to $10.2 million in 2015, then remained steady at $10.2 million in 2016, then remained steady at $10.2 million in 2017, then spiked by 77.05% to $18.1 million in 2018.
  • Its Non-Current Deffered Revenue was $18.1 million in Q4 2018, compared to $12.1 million in Q3 2018 and $10.2 million in Q2 2018.